(0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Omni Shoreham Hotel

Sep 23, 2009 8:00 AM - Sep 24, 2009 2:05 PM

2500 Calvert Street NW, , Washington, DC 20008 , USA

Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications: Current State of the Art and Opportunities to Advance the Science

Back to Agenda

Session 3 - Approaches To Clinical Analysis of CV Risk

Session Chair(s)

Mary Parks, MD

Mary Parks, MD

Director, Div. of Endocrinology and Metabolism Prod., ODE II, CDER

FDA, United States

APPROACHES TO CLINICAL ANALYSIS OF CV RISK

Speaker(s)

Ilan Irony, MD

CV RISK ASSESSMENT STUDIES IN T2DM – DESIGN, PATIENT POPULATIONS, ENDPOINTS

Ilan Irony, MD

Janssen Pharmaceutical Companies of Johnson and Johnson, United States

Senior Director, Global Regulatory Leader

Jennifer Sugg

META-ANALYSES CONSIDERATIONS

Jennifer Sugg

AstraZeneca, United States

Principal Statistician

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.